Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics Inc. is advancing its clinical-stage product candidate ML-007C-MA, designed to provide a differentiated treatment option for schizophrenia and Alzheimer's disease psychosis, showing promising preclinical data with significant improvements in sociability and aggression in relevant mouse models. Phase 1 and preclinical data indicate that ML-007C-MA may achieve better tolerability and dosing convenience compared to currently available medications, which could facilitate its adoption in the market. The therapeutic's favorable pharmacokinetics and safety profile, coupled with compelling target differentiation in circuit-specific pharmacotherapies, position MapLight favorably within the biopharmaceutical landscape.

Bears say

The analysis indicates a negative outlook on MapLight Therapeutics's stock due to several factors, including its late entry into a highly competitive schizophrenia market, where expectations for success are tempered by previous marketing performances of similar drugs with minimal differentiation. Concerns regarding the clinical trial process, including potential conduct issues and delays, have contributed to skepticism around the company's first-phase three readout and elevated the perceived risk profile of its product candidate. Moreover, the current market capitalization of approximately $800 million appears undervalued based on projected peak sales; however, if approval probabilities are lowered to 15%, the discounted cash flow valuation per share could significantly decrease, further underscoring the financial uncertainties associated with the company's prospects.

MPLT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 6 analysts, MPLT has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.